Ravi Goklaney, MD
Psychiatry · Bakersfield, CANPI 1437212636
Payments from drug & device makers
Across 413 payments — averaging $429.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$56K
- Alkermes, Inc.$47K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$41K
- Sunovion Pharmaceuticals Inc.$12K
- E.r. Squibb & Sons, L.L.C.$9K
- AbbVie$8K
- plus $4K from 15 others
What the payments were for
- Consulting fees$34,11919%
- Speaking & faculty fees$117,73666%
- Travel & lodging$11,0276%
- Food & beverage$14,7058%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 73 | $55,863 |
| Alkermes, Inc. | 126 | $47,213 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $40,606 |
| Sunovion Pharmaceuticals Inc. | 27 | $12,348 |
| E.r. Squibb & Sons, L.L.C. | 17 | $8,955 |
| AbbVie(2 entities) | 36 | $8,186 |
| Johnson & Johnson | 9 | $915 |
| Teva Pharmaceuticals USA, Inc. | 13 | $831 |
| Axsome Therapeutics, Inc. | 5 | $499 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $456 |
| Lundbeck LLC | 22 | $433 |
| Neurocrine Biosciences, Inc. | 4 | $340 |
| Vanda Pharmaceuticals Inc. | 2 | $150 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Indivior Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $122 |
| Supernus Pharmaceuticals, Inc. | 1 | $122 |
| Boehringer Ingelheim | 1 | $120 |
| Acadia Pharmaceuticals Inc | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $41 |
| Eisai Inc. | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$118,005
- ARISTADA$60,547
- REXULTI$54,656
- CAPLYTA$39,673
- ARISTADA INITIO$15,137
- LATUDA$12,014
- VRAYLAR$7,868
- INVEGA SUSTENNA$736
- ABILIFY MAINTENA$613
- Auvelity$476
- UZEDY$355
- INVEGA TRINZA$250
- ABILIFY ASIMTUFII$250
- INGREZZA$249
- COBENFY$235
- Austedo XR$234
- NUEDEXTA$125
- SPRAVATO$125
- PERSERIS$125
- Fanapt$125
How this compares
$177,587 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 13 | $18,496 |
| Quetiapine Fumarate | 678 | $10,135 |
| Lurasidone Hcl | 48 | $9,331 |
| TrintellixVortioxetine Hydrobromide | 17 | $8,398 |
| Aripiprazole | 303 | $7,170 |
| Chlorpromazine Hcl | 27 | $6,021 |
| Carbamazepine | 433 | $5,631 |
| Divalproex Sodium | 234 | $4,066 |
| Olanzapine | 304 | $3,298 |
| Oxcarbazepine | 76 | $3,197 |
| Hydroxyzine Hcl | 282 | $3,039 |
| Risperidone | 371 | $2,185 |
| Benztropine Mesylate | 245 | $2,063 |
| Clonazepam | 540 | $1,947 |
| Temazepam | 53 | $1,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $55,863 | $18,49613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $41 | $8,39817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Bakersfield
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.